The FDA rescinded an initial Refusal to File and agreed to review Moderna’s seasonal mRNA influenza vaccine mRNA‑1010 after a Type A meeting, setting a PDUFA target date in August. Moderna proposed an age‑stratified approval pathway — full approval for adults 50–64 and accelerated approval for those 65+ with post‑marketing commitments — and CEO Stéphane Bancel framed the meeting as constructive. Reporting from Politico and industry outlets tied the rapid scheduling to high‑level political pressure, and internal FDA officials have faced public scrutiny as the episode unfolded. A Type A meeting is an FDA mechanism to resolve stalled review interactions; here it allowed Moderna to convert an RTF into an agreed review timeline.